Prevalence and predictors of obesity among individuals with positive hepatitis C antibody in a tertiary referral clinic

Chen, Wendong; Wong, Terence H.; Tomlinson, George; Krahn, Murray; Heathcote, E. Jenny

doi:10.1016/j.jhep.2008.05.013

Cited by 26 publications

(24 citation statements)

References 24 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a more precise way, visceral adiposity index (VAI) is a marker of adipose distribution and dysfunction reflecting nonclassic cardiometabolic risk factors such as altered production of adipocytokines/cytokines, increased lipolysis, and plasma-free fatty acids [79] that has been independently associated not only with steatosis but also with necroinflammatory activity, in patients with genotype 1 CHC [35]. This index was also related to viral load, a finding consistent with several papers that have already suggested a direct association between viral load and BMI [80] and between HCV RNA status and obesity [81]. Overall, these aspects may lead to speculate that, on one hand, adipose tissue could offer fatty substrates and a proinflammatory status promoting HCV replication and that, on the other hand, HCV could molecularly interfere with adipocyte function indirectly, by increasing the inflammatory status and, directly, by colonizing adipocytes or immune cells infiltrating adipose tissue.…”

Section: Visceral Obesitysupporting

confidence: 75%

Metabolic Factors and Chronic Hepatitis C: A Complex Interplay

Macaluso

Maida

Minissale

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

In the last years, several lines of evidence showed how metabolic factors may influence the natural history of patients with chronic hepatitis C. Chronic HCV infection is able to perturb the metabolic homeostasis of the host, in a context of complex interactions where pre-existent metabolic status and genetic background play an important role, allowing us to state that HCV infection is a systemic disease. In this review, we discuss the most recent lines of evidence on the main metabolic factors that are known to be associated with CHC, namely, insulin resistance/type 2 diabetes, steatosis, visceral obesity, atherosclerosis, vitamin D, menopause, fructose and coffee intake, lipoproteins, methylenetetrahydrofolate reductase status, and hyperuricaemia. In particular, we focus on the pathophysiological mechanisms underlying the correlation between HCV infection and metabolic disorders, the impact of metabolic factors on the progression of liver and non-liver-related diseases, and, on the contrary, the possible influence of chronic HCV infection on metabolic features. In this setting, the importance of a multifaceted evaluation of CHC patients and a prompt correction of modifiable metabolic risk factors should be emphasized.

show abstract

Section: Visceral Obesitysupporting

confidence: 75%

Metabolic Factors and Chronic Hepatitis C: A Complex Interplay

Macaluso

Maida

Minissale

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…In this complex interplay between the liver and adipose tissue, HCV could have an important role. It is possible not only that adipose tissue could provide fatty substrates and a proinflammatory status, favouring HCV replication, but also that HCV could interfere with adipocyte function indirectly by increasing the inflammatory status and directly by colonizing adipocytes or immune cells infiltrating adipose tissue [28, 29]. …”

Section: Vai In Nafld and Nashmentioning

confidence: 99%

Visceral Adiposity Index: An Indicator of Adipose Tissue Dysfunction

Amato

Giordano

2014

International Journal of Endocrinology

242

200

View full text Add to dashboard Cite

The Visceral Adiposity Index (VAI) has recently proven to be an indicator of adipose distribution and function that indirectly expresses cardiometabolic risk. In addition, VAI has been proposed as a useful tool for early detection of a condition of cardiometabolic risk before it develops into an overt metabolic syndrome. The application of the VAI in particular populations of patients (women with polycystic ovary syndrome, patients with acromegaly, patients with NAFLD/NASH, patients with HCV hepatitis, patients with type 2 diabetes, and general population) has produced interesting results, which have led to the hypothesis that the VAI could be considered a marker of adipose tissue dysfunction. Unfortunately, in some cases, on the same patient population, there is conflicting evidence. We think that this could be mainly due to a lack of knowledge of the application limits of the index, on the part of various authors, and to having applied the VAI in non-Caucasian populations. Future prospective studies could certainly better define the possible usefulness of the VAI as a predictor of cardiometabolic risk.

show abstract

“…49 Moreover, clinicians should be cognizant of risk factors for specific sleep disorders, such as hypertension and obesity in the case of OSA, especially given that nearly 30% of CHC patients suffer from obesity. 50 The high comorbidity between substance use disorders and CHC requires a comprehensive review of drug and alcohol use as part of the sleep history. Substance use may involve intoxication or withdrawal states that can precipitate sleep difficulties.…”

Section: Screening and Diagnosis Of Sleep Disorders In Chc Patientsmentioning

confidence: 99%

A Review of Sleep Disturbance in Hepatitis C

Sockalingam¹,

Alosaimi²,

Novák³

2010

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

Sleep disturbances occur in up to 60% of patients with chronic hepatitis C (CHC) and is often interrelated with comorbid psychiatric disorders. Moreover, neuropsychiatric complications of interferon-alpha during CHC treatment can manifest as sleep problems. Newly diagnosed sleep disturbance occurs in up to 60% and 30% of untreated CHC patients and patients undergoing interferon-alpha therapy, respectively. However, the presentation of insomnia in patients with CHC is influenced by significant psychiatric comorbidity, such as depression, and medical conditions, such as anemia and hypothyroidism. Therefore, prompt recognition using screening tools and exclusion of comorbid conditions contributing sleep pathology can enhance treatment outcomes. Owing to the paucity of studies, treatment recommendations for sleep disorders in CHC patients are derived from recommendations from general sleep disorder treatment guidelines. Further research is needed to elucidate the efficacy of pharmacological and nonpharmacological treatments of sleep disorders in CHC patients.

show abstract

Prevalence and predictors of obesity among individuals with positive hepatitis C antibody in a tertiary referral clinic

Cited by 26 publications

References 24 publications

Metabolic Factors and Chronic Hepatitis C: A Complex Interplay

Metabolic Factors and Chronic Hepatitis C: A Complex Interplay

Visceral Adiposity Index: An Indicator of Adipose Tissue Dysfunction

A Review of Sleep Disturbance in Hepatitis C

Contact Info

Product

Resources

About